(Q33503141)

27 July 2017

title

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin (English)

1 reference

27 July 2017

1 reference

1 reference

M Ducreux

1

1 reference

27 July 2017

P Rougier

2

1 reference

27 July 2017

A Fandi

3

1 reference

27 July 2017

M C Clavero-Fabri

4

1 reference

27 July 2017

A L Villing

5

1 reference

27 July 2017

F Fassone

6

1 reference

27 July 2017

L Fandi

7

1 reference

27 July 2017

J Zarba

8

1 reference

27 July 2017

J P Armand

9

1 reference

27 July 2017

publication date

1 June 1998

1 reference

27 July 2017

1 reference

27 July 2017

volume

9

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

653-656

1 reference

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

A phase II study of cisplatin in patients with biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241008379

7 January 2021

Identifiers

DOI

10.1023/A:1008241008379

1 reference

27 July 2017

1 reference